TRIM34 is an E3 ubiquitin ligase with multifaceted roles in antiviral defense and disease regulation. As an antiviral protein, TRIM34 restricts lentiviral infections including HIV-1 and SIV by functioning as a capsid-specific restriction factor in conjunction with TRIM5α 12. During influenza A virus infection, TRIM34 promotes programmed necrosis by targeting ZBP1 for K63-linked polyubiquitination, facilitating RIPK3 recruitment 3. Beyond viral defense, TRIM34 exhibits context-dependent functions in disease pathogenesis. In hepatocellular carcinoma, TRIM34 drives ferroptosis resistance by degrading UPF1, thereby stabilizing GPX4 and promoting tumor progression; TRIM34 knockdown sensitizes HCC cells to immunotherapy 4. Conversely, in triple-negative breast cancer, TRIM34 functions as a tumor suppressor by ubiquitinating and degrading FASN, inhibiting fatty acid synthesis and cell proliferation 5. In lung fibrosis, TRIM34 overexpression alleviates disease by degrading HIF-1α, reducing glycolysis and angiogenesis in endothelial cells 6. Additionally, TRIM34 localizes to mitochondria and mediates apoptosis through mitochondrial depolarization and cytochrome c release 7. These findings establish TRIM34 as a critical ubiquitin ligase whose tumor-promoting or tumor-suppressing effects are disease and context-dependent.